TrialSignal
Clinical trial intelligence report
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06514560
Status
RECRUITING
Phase
Observational
Sponsor
Institute of Tropical Medicine, Belgium
Executive brief
Investment-Ready Snapshot
The OPTIMILEISH trial aims to optimize miltefosine treatment for cutaneous leishmaniasis (CL) patients, particularly focusing on dosing strategies for children and understanding parasite dynamics. The study is being conducted by the Institute of Tropical Medicine in collaboration with several Ethiopian and international institutions.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06514560
Indication
Cutaneous Leishmaniases
Modality
small molecule
Target
Cutaneous Leishmaniasis
Intervention
Miltefosine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.